Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Single, dual and pan-PPAR agonists are under development for the pharmacological treatment of NASH
see also:
Elafibranor & Non-alcoholic Steatohepatitis (NASH).
Lanifibranor & Non-alcoholic Steatohepatitis (NASH)
Peroxisome proliferator-activated receptor (PPAR) agonists & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)
…